Lupin Launches Dapagliflozin Tablets In US

Global pharmaceutical major Lupin Ltd announced that the US Food and Drug Administration (USFDA) has approved its Abbreviated New Drug Application (ANDA) for dapagliflozin tablets. The approval covers 5 mg and 10 mg strengths, which are bioequivalent to Farxiga®, a widely prescribed drug for type 2 diabetes management.

Strategic Importance

Dapagliflozin belongs to the SGLT2 inhibitor class, which helps lower blood sugar by preventing glucose reabsorption in the kidneys. Lupin’s entry into this segment in the US market enhances its competitive positioning in diabetes care, one of the fastest-growing therapeutic areas globally.

Market Outlook

The US diabetes market is valued at billions of dollars annually, with strong demand for affordable generics. Lupin’s launch is expected to improve patient access to cost-effective treatment while strengthening its revenue streams from regulated markets. Analysts believe this approval will further consolidate Lupin’s reputation as a leader in generics.

Key Highlights

•⁠  ⁠Lupin receives USFDA approval for dapagliflozin tablets, 5 mg and 10 mg

•⁠  ⁠Tablets are bioequivalent to AstraZeneca’s Farxiga®

•⁠  ⁠Approval expands Lupin’s diabetes portfolio in the US market

•⁠  ⁠Dapagliflozin is part of the SGLT2 inhibitor class for type 2 diabetes

•⁠  ⁠Launch expected to boost patient access and company revenues

Sources: Lupin Press Release, Pharmabiz, CNBC TV18, PR Newswire